1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Pearl Therapeutics, Inc. – Product Pipeline Review – 2013

Pearl Therapeutics, Inc. – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 51 pages

Pearl Therapeutics, Inc. – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Pearl Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Pearl Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Pearl Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Pearl Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Pearl Therapeutics, Inc. - Brief Pearl Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Pearl Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Pearl Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Pearl Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Pearl Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Pearl Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Pearl Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Pearl Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Pearl Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Pearl Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Pearl Therapeutics, Inc. Snapshot 5
Pearl Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Pearl Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Pearl Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pearl Therapeutics, Inc. - Pipeline Products Glance 11
Pearl Therapeutics, Inc. - Late Stage Pipeline 11
Phase III Products/Combination Treatment Modalities 11
Pearl Therapeutics, Inc. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Pearl Therapeutics, Inc. - Early Stage Pipeline Products 13
Pre-Clinical Products/Combination Treatment Modalities 13
Pearl Therapeutics, Inc. - Drug Profiles 14
(glycopyrrolate + formoterol fumarate + inhaled corticosteroid) 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
(glycopyrrolate + formoterol) 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
(PT-002 + PT-009) 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
formoterol fumarate 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
glycopyrrolate 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Pearl Therapeutics, Inc. - Pipeline Products by Route of Administration 23
Pearl Therapeutics, Inc. - Pipeline Products By Mechanism of Action 24
Pearl Therapeutics, Inc. - Recent Pipeline Updates 25
Pearl Therapeutics, Inc. - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Pearl Therapeutics, Inc., Recent Developments 30
Pearl Therapeutics, Inc.- Press Release 30
May 13, 2013: Pearl Therapeutics Initiates Phase III Program Of PT003 For Treatment Of Moderate-to-Severe Chronic Obstructive Pulmonary Disease 30
Dec 01, 2010: Pearl Announces Positive Phase IIb Study Results Of PT003 In COPD Patients 30
May 18, 2010: PEARL Presents Encouraging Data For PT003 For Treatment Of Patients With COPD 31
May 05, 2010: Pearl Therapeutics To Present Data On Bronchodilator Combination Therapeutic For COPD At The American Thoracic Society Annual Meeting 32
Mar 29, 2010: Pearl Therapeutics Announces Positive Results From Phase I Trial Of PT003 For Treatment Of COPD 33
Feb 01, 2010: Pearl Therapeutics Raises $15 Million To Advance PT003, Lama/Laba Combination Bronchodilator For COPD, Into Phase 2b Study 34
Jan 06, 2010: Pearl Therapeutics Announces Positive Results From Phase 2a Trial Of Glycopyrrolate Inhalation Aerosol, PT001 In Chronic Obstructive Pulmonary Disease 35
Jan 04, 2010: Pearl Therapeutics Announces Positive Results From Phase 2A Trial Of Formoterol Inhalation Aerosol In Chronic Obstructive Pulmonary Disease 35
Financial Deals Landscape 37
Pearl Therapeutics, Inc., Deals Summary 37
Pearl Therapeutics, Inc., Pharmaceuticals and Healthcare, Deal Details 38
Venture Financing 38
Pearl Therapeutics Raises US$65 Million In Series D Financing 38
Pearl Therapeutics Secures US$69 Million In Series C Venture Financing 40
Pearl Therapeutics Secures US$15 Million In Series C Venture Financing 42
Pearl Therapeutics Secured US$8 Million In Financing Round 44
Pearl Therapeutics Secures Additional US$18 Million In Series A Financing 46
Pearl Therapeutics Secures US$15.5 Million In Series A Financing 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 51
Disclaimer 51



List of Tables

Pearl Therapeutics, Inc., Key Information 5
Pearl Therapeutics, Inc., Key Facts 5
Pearl Therapeutics, Inc. - Pipeline by Indication, 2013 7
Pearl Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Pearl Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Pearl Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2013 10
Pearl Therapeutics, Inc. - Phase III, 2013 11
Pearl Therapeutics, Inc. - Phase II, 2013 12
Pearl Therapeutics, Inc. - Pre-Clinical, 2013 13
Pearl Therapeutics, Inc. - Pipeline By Route of Administration, 2013 23
Pearl Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 24
Pearl Therapeutics, Inc. - Recent Pipeline Updates, 2013 25
Pearl Therapeutics, Inc., Other Locations 29
Pearl Therapeutics, Inc., Deals Summary 37
Pearl Therapeutics Raises US$65 Million In Series D Financing 38
Pearl Therapeutics Secures US$69 Million In Series C Venture Financing 40
Pearl Therapeutics Secures US$15 Million In Series C Venture Financing 42
Pearl Therapeutics Secured US$8 Million In Financing Round 44
Pearl Therapeutics Secures Additional US$18 Million In Series A Financing 46
Pearl Therapeutics Secures US$15.5 Million In Series A Financing 48



List of Figures

Pearl Therapeutics, Inc. - Pipeline by Indication, 2013 7
Pearl Therapeutics, Inc. - Pipeline by Stage of Development, 2013 8
Pearl Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 9
Pearl Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2013 10
Pearl Therapeutics, Inc. - Pipeline Products By Mechanism of Action, 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.